American journal of veterinary research, 41(1), 123-124 (1980-01-01)
Critical tests were conducted in 11 naturally infected horses to evaluate the anthelmintic activity of parbendazole. Single doses at the rates of 30, 20, 10, 5, or 2.5 mg/kg of body weight were administered by stomach tube to 1, 4
Adult Ascaridia galli and Heterakis gallinae obtained from the fowl (Gallus gallus) were treated in vitro with 10(-2) to 10(-5) M parbendazole and piperazine adipate for 10-60 min at 38 degrees C. Both the compounds at 10(-2) M caused mortality
Journal of veterinary pharmacology and therapeutics, 8(3), 270-275 (1985-09-01)
The ability of parbendazole (PBZ) to potentiate co-administered oxfendazole (OFZ) was investigated. Administration of a range (1.35-36.0 mg/kg) of doses of PBZ with 4.53 mg OFZ/kg demonstrated that significant potentiation occurred at 4.5 mg PBZ/kg. At 4.5 mg PBZ/kg, the
We have shown that the benzimidazole carbamate, parbendazole, is a potent inhibitor of microtubule assembly in vitro and in vivo. Radiolabelled parbendazole was shown to bind to purified tubulin. Immunofluorescence studies using antitubulin antibody showed that parbendazole effectively depolymerizes cytoplasmic
Inhibition of secretion of proteins and triacylglycerol from isolated rat hepatocytes mediated by benzimidazole carbamate antimicrotubule agents.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
